221 related articles for article (PubMed ID: 20535009)
1. Prevention of cardiovascular disease utilizing fibrates--a pooled meta-analysis.
Loomba RS; Arora R
Am J Ther; 2010; 17(6):e182-8. PubMed ID: 20535009
[TBL] [Abstract][Full Text] [Related]
2. Optimal pharmacotherapy to combat the atherogenic lipid triad.
Chapman MJ; Redfern JS; McGovern ME; Giral P
Curr Opin Cardiol; 2011 Sep; 26(5):403-11. PubMed ID: 21730827
[TBL] [Abstract][Full Text] [Related]
3. Treatment of hypertriglyceridemia with fibric acid derivatives: impact on lipid subfractions and translation into a reduction in cardiovascular events.
McCullough PA; Ahmed AB; Zughaib MT; Glanz ED; Di Loreto MJ
Rev Cardiovasc Med; 2011; 12(4):173-85. PubMed ID: 22249508
[TBL] [Abstract][Full Text] [Related]
4. Hyperlipidaemia and cardiovascular disease: do fibrates have a role?
Saha SA; Arora RR
Curr Opin Lipidol; 2011 Aug; 22(4):270-6. PubMed ID: 21519250
[TBL] [Abstract][Full Text] [Related]
5. The association between fibrate use, change in high-density lipoprotein cholesterol, and the risk of cardiovascular disease: a retrospective chart review involving up to 8 years of follow-up.
Nichols GA; Koro CE; Chan W; Bowlin SJ; Sprecher DL
Clin Ther; 2006 Feb; 28(2):243-50. PubMed ID: 16678645
[TBL] [Abstract][Full Text] [Related]
6. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk.
Chapman MJ; Redfern JS; McGovern ME; Giral P
Pharmacol Ther; 2010 Jun; 126(3):314-45. PubMed ID: 20153365
[TBL] [Abstract][Full Text] [Related]
7. The role of fibrates in the prevention of cardiovascular disease--a pooled meta-analysis of long-term randomized placebo-controlled clinical trials.
Saha SA; Kizhakepunnur LG; Bahekar A; Arora RR
Am Heart J; 2007 Nov; 154(5):943-53. PubMed ID: 17967602
[TBL] [Abstract][Full Text] [Related]
8. Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome?
Barter PJ; Rye KA
Arterioscler Thromb Vasc Biol; 2008 Jan; 28(1):39-46. PubMed ID: 17717290
[TBL] [Abstract][Full Text] [Related]
9. Use of fibrates in clinical practice: Queensland Lipid Group consensus recommendations.
Hamilton-Craig I; Kostner KM; Woodhouse S; Colquhoun D
Int J Evid Based Healthc; 2012 Sep; 10(3):181-90. PubMed ID: 22925614
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis.
Lee M; Saver JL; Towfighi A; Chow J; Ovbiagele B
Atherosclerosis; 2011 Aug; 217(2):492-8. PubMed ID: 21592479
[TBL] [Abstract][Full Text] [Related]
11. Fibrates in the secondary prevention of cardiovascular disease (infarction and stroke). Results of a systematic review and meta-analysis of the Cochrane collaboration.
Millan J; Pintó X; Brea A; Blasco M; Hernández-Mijares A; Ascaso J; Diaz A; Mantilla T; Pedro-Botet J
Clin Investig Arterioscler; 2018; 30(1):30-35. PubMed ID: 29395493
[TBL] [Abstract][Full Text] [Related]
12. What does the future hold for niacin as a treatment for hyperlipidaemia and cardiovascular disease?
Ahmed MH
J Cardiovasc Med (Hagerstown); 2010 Nov; 11(11):858-60. PubMed ID: 20686417
[TBL] [Abstract][Full Text] [Related]
13. The role of fibrate treatment in dyslipidemia: an overview.
Katsiki N; Nikolic D; Montalto G; Banach M; Mikhailidis DP; Rizzo M
Curr Pharm Des; 2013; 19(17):3124-31. PubMed ID: 23317397
[TBL] [Abstract][Full Text] [Related]
14. Fibrates: where are we now?
Seth Loomba R; Arora R
Ther Adv Cardiovasc Dis; 2009 Feb; 3(1):91-6. PubMed ID: 19144670
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials.
Birjmohun RS; Hutten BA; Kastelein JJ; Stroes ES
J Am Coll Cardiol; 2005 Jan; 45(2):185-97. PubMed ID: 15653014
[TBL] [Abstract][Full Text] [Related]
16. Statins and diabetes.
Carmena R; Betteridge DJ
Semin Vasc Med; 2004 Nov; 4(4):321-32. PubMed ID: 15861314
[TBL] [Abstract][Full Text] [Related]
17. Fibrates in primary prevention of cardiovascular disease. Comments on the results of a systematic review of the Cochrane Collaboration.
Brea A; Millán J; Ascaso JF; Blasco M; Díaz A; Hernández-Mijares A; Mantilla T; Pedro-Botet JC; Pintó X
Clin Investig Arterioscler; 2018; 30(4):188-192. PubMed ID: 29789212
[TBL] [Abstract][Full Text] [Related]
18. Fibrates and niacin: is there a place for them in clinical practice?
Wierzbicki AS; Viljoen A
Expert Opin Pharmacother; 2014 Dec; 15(18):2673-80. PubMed ID: 25318657
[TBL] [Abstract][Full Text] [Related]
19. The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease.
Hennekens CH; Schneider WR
Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):95-107. PubMed ID: 18095910
[TBL] [Abstract][Full Text] [Related]
20. Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus--a pooled meta-analysis of randomized placebo-controlled clinical trials.
Saha SA; Arora RR
Int J Cardiol; 2010 May; 141(2):157-66. PubMed ID: 19232762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
